ACTRN12608000568314已完成不适用
Phase 3, duble-blind, randomized, parallel study to evaluate the efficacy of glucosamine sulfate and meloxicam administered in combination or glucosamine sulfate and meloxicam administered separately to subjects with mild to moderate osteoarthiritis of the knee or hip
Zodiac Produtos Farmacêuticos S.A.0 个研究点目标入组 270 人开始时间: 2008年11月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 270
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 40 Years 至 60 Years（—）
- 性别
- All
入选标准
- •Patients between 40 and 60 years old
- •- Knee or hip osteoarthritis radiologic and clinical diagnosis
- •- lesion intensity should be mild to moderate (level 2 or 3 in Kellgren-Lawrence classification)
- •- normal laboratory exams
- •- informed consent
排除标准
- •- not used corticosteroids during the last 30 days
- •- not used non steroidal antinflamatory during the last 7 days
- •- immunomodulators previous use
- •- intrarticular medication during the last 6 months
- •- previous surgery in knee or hip and prosthesis use
- •- pregnant
- •- organic disease
研究者
相似试验
进行中（未招募）
不适用
'A phase III, randomised, double-blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg b.i.d.) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute symptomatic venous thromboembolism, following initial treatment (5-10 days) with a parenteral anticoagulant approved for this indication. RE-COVEREUCTR2005-001999-12-ITBOEHRINGER ING.2,550
未知
3 期
Phase III study of subcutaneous injection of MRARheumatoid arthritisJPRN-jRCT2080221083Chugai Pharmaceutical Co., Ltd.330
进行中（未招募）
1 期
A study to test two investigational drugs, dabrafenib and trametinib, for treating melanomaEUCTR2011-006087-49-NLovartis Pharma Services AG340
进行中（未招募）
1 期
A study to test two investigational drugs, dabrafenib and trametinib, for treating melanomaCutaneous melanoma - aggressive form of skin cancers.MedDRA version: 20.0 Level: PT Classification code 10040808 Term: Skin cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-006087-49-SEovartis Pharma Services AG340
已完成
3 期
A Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in subjects with unresectable (Stage IIIc) or metastatic (Stage IV) BRAF V600E/K mutation-positive cutaneous melanoma (MEK115306)melanoma of the skin10040900NL-OMON47344ovartis15